Total Payments
$1.1M
2024 Payments
$131,449
Companies
77
Transactions
1,665
Medicare Patients
13,164
Medicare Billing
$12.7M
Payment Breakdown by Category
Other$744,551 (69.4%)
Consulting$205,697 (19.2%)
Travel$85,459 (8.0%)
Food & Beverage$33,819 (3.2%)
Research$2,184 (0.2%)
Education$487.45 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $743,051 | 280 | 69.3% |
| Consulting Fee | $205,697 | 101 | 19.2% |
| Travel and Lodging | $85,459 | 253 | 8.0% |
| Food and Beverage | $33,819 | 1,019 | 3.2% |
| Unspecified | $2,184 | 1 | 0.2% |
| Honoraria | $1,500 | 1 | 0.1% |
| Education | $487.45 | 10 | 0.0% |
Payments by Type
General
$1.1M
1,664 transactions
Research
$2,184
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $358,494 | 364 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $239,058 | 279 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $127,605 | 113 | $0 (2024) |
| Amgen Inc. | $71,243 | 106 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $64,279 | 54 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $42,459 | 30 | $0 (2017) |
| Merck Sharp & Dohme LLC | $29,883 | 64 | $0 (2024) |
| Ipsen Bioscience Inc | $23,625 | 3 | $0 (2020) |
| PFIZER INC. | $22,065 | 77 | $0 (2024) |
| Lilly USA, LLC | $19,011 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $131,449 | 222 | AstraZeneca Pharmaceuticals LP ($41,379) |
| 2023 | $60,145 | 161 | AstraZeneca Pharmaceuticals LP ($22,307) |
| 2022 | $118,530 | 251 | E.R. Squibb & Sons, L.L.C. ($34,458) |
| 2021 | $105,626 | 90 | AstraZeneca Pharmaceuticals LP ($34,387) |
| 2020 | $125,778 | 111 | AstraZeneca Pharmaceuticals LP ($50,748) |
| 2019 | $159,053 | 286 | AstraZeneca Pharmaceuticals LP ($66,121) |
| 2018 | $215,966 | 312 | AstraZeneca Pharmaceuticals LP ($95,117) |
| 2017 | $155,651 | 232 | E.R. Squibb & Sons, L.L.C. ($76,688) |
All Payment Transactions
1,665 individual payment records from CMS Open Payments — Page 1 of 67
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: ONCOLOGY | ||||||
| 12/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $113.90 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $40.01 | General |
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $100.17 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Oncology | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $620.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/10/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $87.10 | General |
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Oncology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.86 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $970.00 | General |
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $16.48 | General |
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $114.49 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/14/2024 | Amgen Inc. | LUMAKRAS (Drug), Vectibix | Food and Beverage | In-kind items and services | $66.14 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Amneal Pharmaceuticals LLC | AVASTIN (Drug) | Food and Beverage | In-kind items and services | $29.33 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,212.50 | General |
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $23.13 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,988.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $241.20 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | Eli Lilly and Company | $2,184 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 60 | 2,642 | 91,099 | $5.5M | $2.7M |
| 2022 | 73 | 3,568 | 153,462 | $6.6M | $3.2M |
| 2021 | 74 | 3,465 | 150,841 | $6.3M | $3.3M |
| 2020 | 73 | 3,489 | 167,275 | $7.0M | $3.5M |
Total Patients
13,164
Total Services
562,677
Medicare Billing
$12.7M
Procedure Codes
280
All Medicare Procedures & Services
280 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 26 | 32,491 | $1.5M | $769,237 | 52.9% |
| J9228 | Injection, ipilimumab, 1 mg | Office | 2023 | 14 | 4,904 | $1.2M | $637,430 | 53.1% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 26 | 12,827 | $1.0M | $551,652 | 54.1% |
| J9304 | Injection, pemetrexed (pemfexy), 10 mg | Office | 2023 | 17 | 5,158 | $621,716 | $314,958 | 50.7% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 12 | 3,840 | $394,560 | $164,967 | 41.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 164 | 613 | $178,996 | $56,573 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 293 | $55,300 | $26,739 | 48.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 118 | 255 | $33,913 | $15,899 | 46.9% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 50 | 172 | $12,040 | $12,916 | 107.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 75 | $19,819 | $9,905 | 50.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 95 | $17,100 | $8,703 | 50.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 143 | 753 | $26,656 | $7,798 | 29.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 59 | 168 | $23,856 | $7,778 | 32.6% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 12 | 1,505 | $105,726 | $7,114 | 6.7% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 95 | 388 | $22,186 | $6,394 | 28.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 147 | 784 | $11,568 | $6,315 | 54.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 88 | 532 | $18,301 | $5,936 | 32.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 145 | 755 | $19,955 | $5,746 | 28.8% |
| 82024 | Adrenocorticotropic hormone (acth) level | Office | 2023 | 52 | 135 | $14,513 | $5,110 | 35.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 25 | 93 | $11,439 | $4,894 | 42.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $8,748 | $4,353 | 49.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 46 | 78 | $11,778 | $3,621 | 30.7% |
| 96409 | Administration of chemotherapy into vein using push technique | Office | 2023 | 15 | 50 | $12,000 | $3,537 | 29.5% |
| J2997 | Injection, alteplase recombinant, 1 mg | Office | 2023 | 12 | 36 | $4,752 | $2,499 | 52.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 42 | 111 | $7,326 | $2,280 | 31.1% |
About Dr. Yuanbin Chen, MD
Dr. Yuanbin Chen, MD is a Medical Oncology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2008. The National Provider Identifier (NPI) number assigned to this provider is 1467627653.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yuanbin Chen, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $131,449 received in 2024. These payments were reported across 1,665 transactions from 77 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($743,051).
As a Medicare-enrolled provider, Chen has provided services to 13,164 Medicare beneficiaries, totaling 562,677 services with total Medicare billing of $12.7M. Data is available for 4 years (2020–2023), covering 280 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Orlando, FL
- Active Since 04/28/2008
- Last Updated 08/08/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1467627653
Products in Payments
- OPDIVO (Biological) $215,892
- TAGRISSO (Drug) $169,753
- ALUNBRIG (Drug) $164,786
- IMFINZI (Drug) $105,960
- IMFINZI (Biological) $67,761
- ZEPZELCA (Drug) $64,260
- LUMAKRAS (Drug) $44,715
- KEYTRUDA (Biological) $26,956
- BRAFTOVI (Drug) $18,396
- ALIMTA (Drug) $16,872
- TECENTRIQ (Biological) $12,948
- MEKINIST (Drug) $8,751
- SUSTOL (Drug) $6,965
- ONIVYDE (Drug) $5,130
- brigatinib (Drug) $4,847
- XALKORI (Drug) $3,921
- Alecensa (Biological) $3,490
- MEKTOVI (Drug) $2,520
- TAFINLAR (Drug) $2,489
- TEPMETKO (Drug) $2,040
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Orlando
Yasser Khaled, Md, MD
Medical Oncology — Payments: $487,924
Medical Oncology $487,924
Dr. Jacobo Hincapie Echeverri, Md, MD
Medical Oncology — Payments: $6,957
Medical Oncology $6,957
Shelley Szabel
Medical Oncology — Payments: $2,037
Medical Oncology $2,037
Dr. B Alexander, Md, MD
Medical Oncology — Payments: $507.95
Medical Oncology $507.95
Dr. Hatem Hassanein, M.d, M.D
Medical Oncology — Payments: $60.58
Medical Oncology $60.58
Amy Laughlin, M.d, M.D
Medical Oncology — Payments: $19.60
Medical Oncology $19.60